疫苗如何进行调整以应对不断变化的新冠病毒？ - Suppr

Suppr

超能文献

How are vaccines being adapted to meet the changing face of SARS-CoV-2?

作者信息

Stokel-Walker Chris

机构信息

Newcastle upon Tyne.

出版信息

BMJ. 2022 Jun 1;377:o1257. doi: 10.1136/bmj.o1257.

DOI:10.1136/bmj.o1257

PMID:35649582

Abstract

摘要

相似文献

How are vaccines being adapted to meet the changing face of SARS-CoV-2?疫苗如何进行调整以应对不断变化的新冠病毒？

BMJ. 2022 Jun 1;377:o1257. doi: 10.1136/bmj.o1257.

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）逃脱了自然免疫，引发了关于疫苗和疗法的问题。

Nat Med. 2021 May;27(5):759-761. doi: 10.1038/s41591-021-01347-0.

Special focus 'SARS-CoV-2 / COVID-19: advances in developing vaccines and immunotherapeutics'.特别关注“SARS-CoV-2 / COVID-19：疫苗和免疫疗法研发进展”

Hum Vaccin Immunother. 2020 Dec 1;16(12):2888-2890. doi: 10.1080/21645515.2020.1847952.

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant.不同佐剂对基于蛋白质的亚单位疫苗引发的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其德尔塔变种的免疫反应的影响。

Viruses. 2022 Feb 28;14(3):501. doi: 10.3390/v14030501.

[COVID-19 vaccine safety].[新冠病毒疫苗安全性]

Rev Peru Med Exp Salud Publica. 2021 Oct-Dec;38(4):634-642. doi: 10.17843/rpmesp.2021.384.9308. Epub 2022 Apr 1.

Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice.S 蛋白 493 位和 498 位的 Q 突变为 SARS-CoV-2 在小鼠体内的适应性进化提供了条件。

EBioMedicine. 2021 May;67:103381. doi: 10.1016/j.ebiom.2021.103381. Epub 2021 May 14.

SARS-CoV-2 candidate vaccines - composition, mechanisms of action and stages of clinical development.严重急性呼吸综合征冠状病毒2候选疫苗——成分、作用机制及临床开发阶段

Allergy. 2021 Jun;76(6):1922-1924. doi: 10.1111/all.14714. Epub 2021 Jan 7.

3-dose of RBD vaccine is sufficient to elicit a long-lasting memory response against SARS-CoV-2 infection.三剂重组刺突蛋白（RBD）疫苗足以引发针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的持久记忆反应。

Signal Transduct Target Ther. 2022 Mar 14;7(1):84. doi: 10.1038/s41392-022-00937-9.

COVID-19 Vaccination Limits Systemic Danger Signals in SARS-CoV-2 Infected Patients.COVID-19 疫苗接种限制 SARS-CoV-2 感染患者的全身危险信号。

Viruses. 2022 Mar 9;14(3):565. doi: 10.3390/v14030565.

SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.SARS-CoV-2 疫苗：成就斐然，仍有许多需要学习。

Ann Intern Med. 2021 May;174(5):687-690. doi: 10.7326/M21-0111. Epub 2021 Jan 19.

引用本文的文献

Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent Vaccines.探索新冠病毒二价疫苗接种后严重不良事件报告的时空特征。

Res Sq. 2025 Mar 3:rs.3.rs-6096098. doi: 10.21203/rs.3.rs-6096098/v1.

Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.美国 COVID-19 疫苗的不良事件：时空分析。

JMIR Public Health Surveill. 2024 Jul 15;10:e51007. doi: 10.2196/51007.

Epidemiology of COVID-19 outbreaks in aged care facilities during postvaccine period: a systematic review and meta-analysis.疫苗接种后老年护理机构中 COVID-19 疫情的流行病学：系统评价和荟萃分析。

BMJ Open. 2024 Mar 14;14(3):e073555. doi: 10.1136/bmjopen-2023-073555.

Bioengineered small extracellular vesicles deliver multiple SARS-CoV-2 antigenic fragments and drive a broad immunological response.生物工程化的小细胞外囊泡递送多种 SARS-CoV-2 抗原片段并引发广泛的免疫应答。

J Extracell Vesicles. 2024 Feb;13(2):e12412. doi: 10.1002/jev2.12412.

SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.SARS-CoV-2 奥密克戎变异株：疾病负担、对疫苗有效性的影响以及对变异株适应性疫苗的需求。

Front Immunol. 2023 May 23;14:1130539. doi: 10.3389/fimmu.2023.1130539. eCollection 2023.

Scalable agroinfiltration-based production of SARS-CoV-2 antigens for use in diagnostic assays and subunit vaccines.基于可扩展的农杆菌浸润技术生产 SARS-CoV-2 抗原，用于诊断检测和亚单位疫苗。

PLoS One. 2022 Dec 14;17(12):e0277668. doi: 10.1371/journal.pone.0277668. eCollection 2022.

Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?针对新冠病毒的二价疫苗接种会增加波兰人接种新冠疫苗的意愿吗？

Vaccines (Basel). 2022 Oct 3;10(10):1658. doi: 10.3390/vaccines10101658.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验